ABIO:NSD-ARCA Biopharma Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.06

Change

+0.01 (+0.49)%

Market Cap

USD 0.03B

Volume

0.02M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

ABIO Stock Forecast & Price:
Based on the ARCA Biopharma Inc stock forecasts from 0 analysts, the average analyst target price for ARCA Biopharma Inc is not available over the next 12 months. ARCA Biopharma Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of ARCA Biopharma Inc is Neutral, which is based on 5 positive signals and 6 negative signals. At the last closing, ARCA Biopharma Inc’s stock price was USD 2.06. ARCA Biopharma Inc’s stock price has changed by -0.96% over the past week, -5.50% over the past month and -15.23% over the last year.

No recent analyst target price found for ARCA Biopharma Inc
No recent average analyst rating found for ARCA Biopharma Inc

About ARCA Biopharma Inc (ABIO:NSD)

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical ...Read More

Company Website : https://www.arcabio.com

Address : 10170 Church Ranch Way, Westminster, CO, United States, 80021

Employees : 17

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.82

52 Week High : 2.59

Short Ratio : 2.31

52 Week Low : 1.71

Shorted Shares : 50,508

200 Day Moving Average : 2.26

Shorted Shares Previous Month : 50,898

50 Day Moving Average : 2.07

Shares Held By Insiders : 0.74%

Short Percentage : 0.43%

Shares Held by Institutions : 38.64%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

+1.03 (+0.33%)

 USD80.34B 24.98 17.08
REGN Regeneron Pharmaceuticals Inc

-5.40 (-0.73%)

 USD80.18B 15.51 11.82
MRNA Moderna Inc

-2.23 (-1.27%)

 USD67.38B 6.33 4.43
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

+2.12 (+1.31%)

 USD37.58B 3.75 1.66
GMAB Genmab AS

-0.52 (-1.16%)

 USD29.87B 37.36 3.53
ALNY Alnylam Pharmaceuticals Inc

-4.41 (-2.11%)

 USD26.17B N/A -26.97
SGEN Seagen Inc

-3.85 (-3.18%)

 USD22.92B 55.02 -38.67
ARGX argenx NV ADR

-1.28 (-0.34%)

 USD21.49B N/A -20.63
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing ABIO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.19% 86% B 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.19% 85% B 69% D+
Trailing 12 Months  
Capital Gain -12.90% 83% B 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.90% 83% B 59% F
Trailing 5 Years  
Capital Gain -91.20% 26% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -91.20% 26% F 8% F
Average Annual (5 Year Horizon)  
Capital Gain -31.31% 18% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.31% 18% F 8% F
Risk Return Profile  
Volatility (Standard Deviation) 26.16% 88% B+ 61% D-
Risk Adjusted Return -119.72% 4% F 1% F
Market Capitalization 0.03B 26% F 17% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.76 30% F 50% F
Price/Book Ratio 0.70 77% C+ 84% B
Price / Cash Flow Ratio -1.57 40% F 53% F
EV/EBITDA 0.94 13% F 41% F
Management Effectiveness  
Return on Equity -29.05% 81% B- 39% F
Return on Invested Capital -39.64% 62% D- 28% F
Return on Assets -16.57% 80% B- 30% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 2.31 66% D 54% F
Short Percent 0.43% 87% B+ 77% C+
Beta 1.82 17% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.